CHICAGO (AP) — CHICAGO (AP) — Xeris Biopharma Holdings, Inc. (XERS) on Thursday reported a loss of $15 million in its second quarter.
On a per-share basis, the Chicago-based company said it had a loss of 10 cents.
The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 11 cents per share.
The company posted revenue of $48.1 million in the period, also beating Street forecasts. Three analysts surveyed by Zacks expected $46.8 million.
Xeris Biopharma expects full-year revenue in the range of $190 million to $200 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XERS at https://www.zacks.com/ap/XERS
/Micron%20Technology%20Inc_billboard-by%20Poetra_RH%20via%20Shutterstock.jpg)
/Microsoft%20France%20headquarters%20by%20JeanLuclchard%20via%20Shutterstock.jpg)
/Palantir%20(PLTR)%20by%20Piotr%20Swat%20via%20Shutterstock.jpg)
/International%20Business%20Machines%20Corp_%20logo%20on%20storage%20rack-by%20Nick%20N%20A%20via%20Shutterstock.jpg)
